PMID- 29966024
OWN - NLM
STAT- MEDLINE
DCOM- 20190625
LR  - 20210109
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 9
DP  - 2018
TI  - Exploring Immune Development in Infants With Moderate to Severe Atopic 
      Dermatitis.
PG  - 630
LID - 10.3389/fimmu.2018.00630 [doi]
LID - 630
AB  - BACKGROUND: Atopic dermatitis (AD) is the most common chronic inflammatory skin 
      disease in infancy with a complex pathology. In adults, the clinical severity of 
      AD has been associated with increases in T helper cell type (Th) 2, Th22, and 
      Th17 serum markers, including high levels of CC chemokine ligand (CCL) 17 and 
      CCL22 chemokines. OBJECTIVE: To explore the possible association between serum 
      chemokine levels and AD severity in infants with moderate-to-severe AD and 
      elevated immunoglobulin E (IgE). SUBJECTS AND METHODS: Serum samples (n = 41) 
      obtained from a randomized, double-blind, and clinical dietary intervention study 
      were used to study biomarkers in infants with AD. Baseline- and post-intervention 
      samples (4 months) were used, six chemokines and nine ratios thereof were 
      analyzed using Luminex and correlated to AD severity. In the initial study, the 
      infants were randomized to receive extensively hydrolyzed whey-based formula 
      without (control) or with short-chain galacto-oligosaccharides/long-chain 
      fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active). RESULTS: 
      31 Infants up to 11 months of age, with an objective-SCORAD score (oSCORAD) >/= 20 
      and elevated total-IgE and/or specific-IgE levels were included. In time, the 
      median oSCORAD decreased in both groups by -8 (control, p < 0.05; active, 
      p < 0.01). Irrespective of dietary intervention, several changes in Th2 
      chemokines (CCL17 and CCL22), inflammatory chemokine (CCL20), and the Th1 
      chemokine, CXC chemokine ligand (CXCL) 9, were detected over time. Overall CCL17 
      correlated to oSCORAD (r = 0.446, p < 0.01). After 4 months of dietary 
      intervention, CXCL9 was higher (p < 0.01) in the active group compared with 
      control [active, 2.33 (1.99-2.89); controls, 1.95 (1.77-2.43) log 10 median 
      (range)]. In addition, a reduction in Th2/Th1 chemokine ratios for CCL17/CXCL9, 
      CCL22/CXCL9, CCL20/CXCL10, and CCL20/CXCL11 was detected associated with the 
      active intervention. CONCLUSION: While this study is small and exploratory in 
      nature, these data contribute to immune biomarker profiling and understanding of 
      AD in infants.
FAU - Hulshof, Lies
AU  - Hulshof L
AD  - Emma Children's Hospital Academic Medical Centre, Department of Paediatric 
      Respiratory Medicine and Allergy, University of Amsterdam, Amsterdam, 
      Netherlands.
FAU - Overbeek, Saskia A
AU  - Overbeek SA
AD  - Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht 
      University, Utrecht, Netherlands.
AD  - Nutricia Research, Utrecht, Netherlands.
FAU - Wyllie, Anne L
AU  - Wyllie AL
AD  - Department of Paediatric Immunology and Infectious Diseases, University Medical 
      Centre Utrecht, Wilhelmina Children's Hospital, Utrecht, Netherlands.
FAU - Chu, Mei Ling J N
AU  - Chu MLJN
AD  - Department of Paediatric Immunology and Infectious Diseases, University Medical 
      Centre Utrecht, Wilhelmina Children's Hospital, Utrecht, Netherlands.
FAU - Bogaert, Debby
AU  - Bogaert D
AD  - Department of Paediatric Immunology and Infectious Diseases, University Medical 
      Centre Utrecht, Wilhelmina Children's Hospital, Utrecht, Netherlands.
FAU - de Jager, Wilco
AU  - de Jager W
AD  - Laboratory of Translational Immunology, Department of Paediatric Immunology, 
      University Medical Centre Utrecht, Utrecht, Netherlands.
FAU - Knippels, Leon M J
AU  - Knippels LMJ
AD  - Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht 
      University, Utrecht, Netherlands.
AD  - Nutricia Research, Utrecht, Netherlands.
FAU - Sanders, Elisabeth A M
AU  - Sanders EAM
AD  - Department of Paediatric Immunology and Infectious Diseases, University Medical 
      Centre Utrecht, Wilhelmina Children's Hospital, Utrecht, Netherlands.
FAU - van Aalderen, Wim M C
AU  - van Aalderen WMC
AD  - Emma Children's Hospital Academic Medical Centre, Department of Paediatric 
      Respiratory Medicine and Allergy, University of Amsterdam, Amsterdam, 
      Netherlands.
FAU - Garssen, Johan
AU  - Garssen J
AD  - Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht 
      University, Utrecht, Netherlands.
AD  - Nutricia Research, Utrecht, Netherlands.
FAU - Van't Land, Belinda
AU  - Van't Land B
AD  - Nutricia Research, Utrecht, Netherlands.
AD  - Department of Paediatric Immunology and Infectious Diseases, University Medical 
      Centre Utrecht, Wilhelmina Children's Hospital, Utrecht, Netherlands.
FAU - Sprikkelman, Aline B
AU  - Sprikkelman AB
AD  - Emma Children's Hospital Academic Medical Centre, Department of Paediatric 
      Respiratory Medicine and Allergy, University of Amsterdam, Amsterdam, 
      Netherlands.
AD  - Department of Paediatric Pulmonology and Paediatric Allergology, University of 
      Groningen, University Medical Centre Groningen, Beatrix Children's Hospital, 
      Groningen, Netherlands.
CN  - Clinical Study Group
LA  - eng
SI  - NTR/NTR3447
GR  - SCAF/16/03/CSO_/Chief Scientist Office/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20180329
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Biomarkers)
RN  - 0 (CCL17 protein, human)
RN  - 0 (CXCL9 protein, human)
RN  - 0 (Chemokine CCL17)
RN  - 0 (Chemokine CXCL9)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adult
MH  - Biomarkers/*blood
MH  - Chemokine CCL17/*blood
MH  - Chemokine CXCL9/*blood
MH  - Dermatitis, Atopic/diagnosis/diet therapy/*immunology
MH  - Disease Progression
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Infant
MH  - *Infant Formula
MH  - Male
MH  - Severity of Illness Index
MH  - Th1-Th2 Balance
PMC - PMC5884950
OTO - NOTNLM
OT  - T helper cell type 2/T helper cell type 1 response
OT  - atopic dermatitis
OT  - atopic dermatitis severity
OT  - chemokine profiles
OT  - dietary intervention
OT  - infants
FIR - Blauw, A
IR  - Blauw A
FIR - Dontje, B
IR  - Dontje B
FIR - Duijvestein, Y C M
IR  - Duijvestein YCM
FIR - de Boom, W H C
IR  - de Boom WHC
FIR - Groot, I
IR  - Groot I
FIR - Boks, M
IR  - Boks M
FIR - van Kooyk, Y
IR  - van Kooyk Y
FIR - Fandri, D H H
IR  - Fandri DHH
FIR - Hijnen, D
IR  - Hijnen D
FIR - Middelkamp-Hup, M A
IR  - Middelkamp-Hup MA
FIR - Papi, B
IR  - Papi B
FIR - Roelofs, M
IR  - Roelofs M
FIR - Rijnierse, A
IR  - Rijnierse A
FIR - Veening, D
IR  - Veening D
FIR - Prakken, B J
IR  - Prakken BJ
FIR - Ten Tusscher, G W
IR  - Ten Tusscher GW
FIR - Tupker, R A
IR  - Tupker RA
FIR - Willemsen, L E M
IR  - Willemsen LEM
EDAT- 2018/07/03 06:00
MHDA- 2018/07/03 06:01
PMCR- 2018/01/01
CRDT- 2018/07/03 06:00
PHST- 2017/12/04 00:00 [received]
PHST- 2018/03/13 00:00 [accepted]
PHST- 2018/07/03 06:00 [entrez]
PHST- 2018/07/03 06:00 [pubmed]
PHST- 2018/07/03 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2018.00630 [doi]
PST - epublish
SO  - Front Immunol. 2018 Mar 29;9:630. doi: 10.3389/fimmu.2018.00630. eCollection 
      2018.